Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"AGENDA" is the name of the program...extremely fitting.
Randy also owns stock!
Get ready for a rude awakening.
If Leronlimab had no value, it would not be in the news, the SP would be much lower, and we would not be talking about it.
https://twitter.com/YoDoctorYo/status/1391410154936152068?s=20
While we show 24% efficacy in our CD-12 and yes that percentage is correct it was in the results
If Leronlimab wasn’t effective it would have been shutdown a long time ago
Actually in my medical opinion , by the results , Leronlimab is the best drug in the world right now
CytoDyn's leronlimab offers the best "shot" going, for recovery. In fact - why wait until you're almost dead to begin treatment?
I do not see how he can survive, as CEO, if this is not a significant milestone.
" If we saved lives and I only broke even I'm fine with that." -- this is the only reason why I haven't sold a single share
I don't think I'd be comfortable wishing someone bad results on peoples misfortunes
This looks like a not-so-subtle dig on Nader.
There is a Facebook site for that! We would never exploit patients like that! https://t.co/4Ez848V9UR
— Bruce K. Patterson MD (@brucep13) May 9, 2021
Lenzilumab is a GM-CSF inhibitor. The "M" in GM-CSF is macrophage.
CAR-T
https://www.nature.com/articles/s41408-021-00459-7
https://www.nature.com/articles/s41421-021-00255-4
https://www.targetedonc.com/view/lenzilumab-plus-axi-cel-achieves-responses-in-100-of-patients-with-dlbcl-with-limited-toxicity-in-small-study
https://www.healio.com/news/hematology-oncology/20210422/lenzilumab-before-cart-induces-high-response-rates-without-severe-toxicities
Covid
https://www.bbc.com/news/health-56352128
https://immunology.sciencemag.org/content/6/57/eabg9873
https://directorsblog.nih.gov/2021/04/13/mapping-severe-covid-19-in-the-lungs-at-single-cell-resolution/
https://www.nature.com/articles/s41586-021-03569-1
https://www.pharmaceutical-technology.com/news/humanigen-lenzilumab-improves-survival/
HGEN Summary
https://www.reddit.com/r/Humanigen/comments/n1a4q4/another_awesome_dd/
Why is this stock struggling to break $20? Why are there no buyers? Could this be part of the reason?
The EUA for early stage severe patients should come within a month. But that is just the start. Patients who eventually become severe and die show elevated GM-CSF in the early stages of Covid. Obviously, it isn't possible to treat all milds with lenzilumab. And we don't have the testing resources to test all milds to see who has elevated GM-CSF.
But testing the blood of moderates for elevated GM-CSF might not be that far away. And eventually they might be able to even test all of the mild patients. If lenz has 3-fold efficacy treating early severe patients (and under 85yo) then imagine how crazy high its efficacy would be if it treated the 10%-20% of early stage patients who have elevated GM-CSF?
Nader is known to do dumb things.
Second, the observations pertaining to benefits in the population that had CRP<150 mg/L and age <85 were exploratory.
From Bio4 on ST:
https://www.sundayguardianlive.com/news/breakthrough-treatments-covid-19
With the crisis pushing us to innovate, we are learning about newer drugs that can fight the virus’ effects. One such promising medication is lenzilumab, a drug created by Humanigen, based in the United States. Lenzilumab targets the initiation of “cytokine storm,” the hyper inflammation consequent to SARS-Cov-2 infection that leads to critical illness in many patients. In the LIVE-AIR phase 3 clinical trial, lenzilumab improved the likelihood of survival and/or ventilation by 54%, over and above remdesivir and dexamethasone, in newly hospitalized Covid-19 patients, who required supplemental oxygen but had not yet progressed to invasive mechanical ventilation. The effect of this one-day treatment was most beneficial in patients who were less than 85 years old and had a biomarker of early hyperinflammatory response; in which lenzilumab improved the likelihood of survival and/or ventilation by nearly three-fold.
I referred to the csp program and said other countries may try to implement something similar. Please read before you criticize! I said nothing about regulatory boards.
I believe results from 28 are very important
CytoDyn/leronlimab to sell in Europe by June/July without a doubt. I would say most likely Germany first then Spain or France and the rest to follow. UK most likely to take up the rear position.
I am going to enjoy this years BBQ with friends and family all discussing the high probability that UK authorizes emergency usage of leronlimab toute suite and then watch France follow in line, then Germany and Spain.
But,,, I also predict that Trump steps in and insures priority goes to the USA to keep America Safe Again as he likes to say. All China Virus sufferers appreciate what CytoDyn will deliver.
So now that CytoDyn's Leronlimab has crossed the pond, will it take the Chunnel and see another liberation of Paris and then another Berlin Airlift. Very Very Likely IMO now the way things are shaping up.
Across the channel in France as well. Depression is hitting numbers never seen before. They want to make a deal. As NP said they are asking for CYDY to get involved.
We will uplist. That is a given.
Doctors and scientist are lining up for Leronlimab. We will have it before the election and the news will be brilliantly displayed in a bigly fashion.
Lenzilumab is a GM-CSF inhibitor. The "M" in GM-CSF is macrophage.
CAR-T
https://www.nature.com/articles/s41408-021-00459-7
https://www.nature.com/articles/s41421-021-00255-4
https://www.targetedonc.com/view/lenzilumab-plus-axi-cel-achieves-responses-in-100-of-patients-with-dlbcl-with-limited-toxicity-in-small-study
https://www.healio.com/news/hematology-oncology/20210422/lenzilumab-before-cart-induces-high-response-rates-without-severe-toxicities
Covid
https://www.bbc.com/news/health-56352128
https://immunology.sciencemag.org/content/6/57/eabg9873
https://directorsblog.nih.gov/2021/04/13/mapping-severe-covid-19-in-the-lungs-at-single-cell-resolution/
https://www.nature.com/articles/s41586-021-03569-1
https://www.pharmaceutical-technology.com/news/humanigen-lenzilumab-improves-survival/
HGEN Summary
https://www.reddit.com/r/Humanigen/comments/n1a4q4/another_awesome_dd/
https://www.reddit.com/r/CYDY/comments/n74uf6/leronlimab_mentioned_as_the_best_of_four_drugs/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
BTW, who is to going to buyout HGEN and at an astronomical price? Because there is nobody circling the wagon.
Is this a "just in case" strategy, where Cytodyn still hopes LL would work well for severe patients if tested in a larger population?
So promising GILD walked away.
Fair, but it was a combined trial. We do not know the demand/ratio of critical or severe that was available. Maybe there were more critical that wanted to get in, but the design only allowed a specific amount. With them being separate, they can go as fast as the demand of critical/severe are available (that meets the trial criteria). Probably the reason they are separated.
The critical trial only has 300ish patients. So, Oct or before for 120 patients (40%) is possible considering the high number of hospitalizations in Brazil. However, the severe trial of 1100ish patients is probably Oct/Nov later, in not Jan.
proven in a much larger population in the next 3 months
Very sorry DonDonDonDon. But "a lie"? Isn't that kind of harsh?
I stated this stat incorrectly.
Leronlimab reduced deaths 82% at 14 days, vs SOC death reduction.
That's quite a powerful stat, correct, surely you do agree?
It also doesn't heal 1 out of 4 with critical patients. That is the relative benefit, not the absolute benefit. Critical patients in the leronlimab arm had a 38% mortality. Critical patients in the placebo arm had a 47% mortality rate. 47% is 24% larger than 38% but it is an absolute benefit of 9%. Please stop repeating the lie that it saves 1 out of 4.
Leronlimab, is saving the lives of 82% of their critical cv19 patients
Virologix has been proven to be 82 % better than Gilead's liver damaging drug in certain age groups and conditions.
Some suggest that they will mention trial data on the 28?
SWOV also relatively improved by 92% in subjects who received
both corticosteroids and remdesivir (1.92; 1.20-3.07, nominal p=0.0067); by 2.96-fold in
subjects with CRP<150 mg/L and age <85 years (2.96; 1.63–5.37, nominal p=0.0003);
and by 88% in subjects hospitalized ≤2 days prior to randomization (1.88; 1.13-3.12,
nominal p=0.015). Survival was improved by 2.17-fold in subjects with CRP<150 mg/L
and age <85 years (2.17; 1.04-4.54, nominal p=0.040)
Nice start to the trading day.
XBI is up in premarket. HGEN should rebound easily and quickly if there is a short attack.
I have been a shareholder since 2012.
Ohhh, is that how pharma's operate these days?
Claim 1.2M vials but in vats or frozen.
Amateur hour.
Lenzilumab is a GM-CSF inhibitor. The "M" in GM-CSF is macrophage.
CAR-T
https://www.nature.com/articles/s41408-021-00459-7
https://www.nature.com/articles/s41421-021-00255-4
https://www.targetedonc.com/view/lenzilumab-plus-axi-cel-achieves-responses-in-100-of-patients-with-dlbcl-with-limited-toxicity-in-small-study
https://www.healio.com/news/hematology-oncology/20210422/lenzilumab-before-cart-induces-high-response-rates-without-severe-toxicities
Covid
https://www.bbc.com/news/health-56352128
https://immunology.sciencemag.org/content/6/57/eabg9873
https://directorsblog.nih.gov/2021/04/13/mapping-severe-covid-19-in-the-lungs-at-single-cell-resolution/
https://www.nature.com/articles/s41586-021-03569-1
https://www.pharmaceutical-technology.com/news/humanigen-lenzilumab-improves-survival/
HGEN Summary
https://www.reddit.com/r/Humanigen/comments/n1a4q4/another_awesome_dd/